-
Akorn (AKRX) PT Lowered to $4 at RBC Capital
-
Akorn (AKRX) FDA Warning Letter was a 'Known Risk' - RBC
-
Akorn (AKRX) PT Lowered to $6 at RBC Capital
-
Akorn (AKRX) Plunges as Hopes in Delaware Trial Sinks
-
Akorn (AKRX) Generic Voltaren Gel Approved - RBC
-
Akorn (AKRX) PT Lowered to $9 at RBC Capital
-
Akorn (AKRX) PT Lowered to $10 at RBC Capital
-
Akorn (AKRX) 'Worst-Case Scenario', Stock Could Settle ~$6-$8 Today - RBC
-
Akorn (AKRX): Post-Trial Hearing Could Signal Direction of Decision - RBC
-
Akorn (AKRX) PT Raised to $27 at RBC Capital on Higher Likelihood of Deal Closure
-
Akorn (AKRX) Risk/Reward Still Favorable - RBC
-
RBC Has an Unchanged View on Akorn (AKRX) Merger Following Expert Call
-
RBC Still Sees a Path to Closing of Akorn (AKRX) Merger
-
Akorn (AKRX) Gains as RBC Sees a Path to Closing
-
RBC Capital Likes Akorn (AKRX) Upside Risk/Reward from Here; PT Lowered to $25
-
Akorn (AKRX): Takeout Price Hard To Justify, Repricing Could Happen - RBC
-
Akorn (AKRX): Valuation Here Is Fair, More Is Compelling - RBC
-
RBC Capital Reiterates Sector Perform Rating on Akorn (AKRX) Following Reports Fresenius in Take-Out Discussions
-
Akorn (AKRX) PT Lowered to $21 at RBC Capital on 2017 Guidance 'Reset' and 'Struggle With Growth Story'
-
RBC Capital Downgrades Akorn (AKRX) to Sector Perform
-
Notable Analyst Rating Changes 9/15: (GPN) (AKRX) (EXTR) Upgraded; (VFC) (FGP) (ATRA) Downgraded
-
Akorn (AKRX): EPS Upside Coming From Competitor Delay - RBC
-
Akorn (AKRX) Ephedrine NDA Delayed - RBC Capital
-
RBC Remains Positive on Akorn (AKRX) as Ephedrine NDA Still Not Approved
-
Akorn (AKRX) Highlighted at RBC After Sagent (SGNT) Acquired by Foreign Player
-
Akorn (AKRX) Lack of Disaster Brings Pipeline Into Focus - RBC
-
RBC Capital Cuts Price Target on Akorn (AKRX) Ahead of March Update
-
RBC Highlights Bull Case and Milestones for Akorn (AKRX)
-
Akorn (AKRX) Provided Realistic Outlook on Path to Re-File - RBC Capital
-
Akorn (AKRX) to Request NASDAQ Filing Extension; RBC Capital Reiterates Outperform
-
Notable Analyst Rating Changes 9/29: (AKRX) (CHS) (NKE) Upgraded; (DRC) (MAT) (KS) Downgraded
-
RBC Capital Upgrades Akorn (AKRX) to Outperform
-
RBC Capital Starts Akorn (AKRX) at Sector Perform
-
RBC Capital Upgrades Akorn (AKRX) to Sector Perform

